HR+/HER2- advanced breast cancer: How do the latest data on CDK4/6 inhibitors inform clinical decision-making?
touchEXPERT OPINIONS for touchONCOLOGY
Listen to leading experts in breast cancer share their opinion on the latest data which may help guide the use of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer.
The experts
Dr Luca Malorni - Hospital of Prato, Italy
Prof. Aleix Prat - Hospital Clínic Barcelona, Spain
Dr Barbara Pistilli - Gustave Roussy, Villejuif, France
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Novartis and is provided by touchIME.
For further information visit our website…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.